Transcenta Holding, a Chinese biopharmaceutical company with the capabilities of drug discovery, process development, clinical development and process integration, announced the successful completion of a US$100 million series B+ round of financing. This round of financing is jointly led by China Resources Zhengda Life Science Fund and a unit of Fortune Venture Capital. Epiphron Capital, […]
Chinese Biotech Firm Transcenta Raises $100M Round comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.